Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,617 across all filing types
Latest filing 2020-01-10 Director's Dealing
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
108年12月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabular disclosure of shareholdings and pledged shares by insiders and directors of the company 景岳生物科技股份有限公司. It lists share counts, pledged shares, and related insider information. There is no indication of financial statements, management discussion, earnings data, or meeting materials. The content is focused on insider shareholdings and pledges, which corresponds to insider transactions or director dealings. Given the nature of the data (insider holdings and pledges) and the absence of other report types, this fits best under Director's Dealing (DIRS). The document length is 2619 characters, which is consistent with a detailed insider shareholding report rather than a brief announcement or a full financial report.
2020-01-10 Chinese
108年12月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a company named 景岳, providing information about fund loans and endorsement guarantees for a specific month (December of 民國108年, which corresponds to 2019). The content is very short (601 characters) and consists mainly of tabular data showing zero balances and no guarantees. There is no detailed financial statement, no management discussion, no earnings highlights, no meeting materials, or any other comprehensive report content. This type of document is a regulatory disclosure of specific financial information but does not constitute a full report or announcement of a report. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2020-01-10 Chinese
108年12月營業收入
Regulatory Filings Classification · 95% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 景岳, with data for December 2019 (民國108年12月). It includes percentage changes compared to the previous year and explanatory notes about accounting standards (IFRS) and reporting practices. The document is very short (767 characters) and contains no detailed financial statements or management discussion. It appears to be a brief financial data disclosure rather than a full report or announcement of a meeting or vote. It does not fit the definitions of Annual Report, Interim Report, Earnings Release, or other detailed filings. Given the nature and length, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other categories.
2020-01-10 Chinese
公告本公司申請股票上櫃轉上市時所出具之承諾事項 暨其後續執行情形
Regulatory Filings Classification · 95% confidence The document is a short announcement (768 characters) from a listed company (景岳生物科技股份有限公司) regarding its commitments and subsequent execution related to its application for stock listing transfer from OTC to the main board. It references compliance with a Taiwan Stock Exchange regulation and reports on the status of audit-related commitments for the fiscal year ending 108/12/31 (Taiwan calendar year). The document does not contain financial statements or detailed financial data but rather a compliance and status update. It is not a full report like an Annual Report or Interim Report, nor is it a certification letter or voting result. Given its nature as a regulatory compliance announcement related to listing and audit commitments, and its short length, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2020-01-07 Chinese
108年11月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, supervisors, and senior management, with specific numbers of shares held, changes in holdings, and related notes. The content focuses on personal share transactions and holdings by company directors and executives. There is no indication of financial statements, earnings data, or report announcements. The document is not a general regulatory filing or a report publication announcement but a detailed insider shareholding disclosure. Therefore, the document fits the category of Director's Dealing (DIRS).
2019-12-12 Chinese
108年11月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by company insiders, including directors, supervisors, and executives. It lists their share counts, pledged shares, and related ratios. This type of disclosure is typical of insider share transactions or holdings disclosures. There is no indication of financial results, management discussion, or meeting materials. The document is not a report or announcement of a meeting or vote, nor is it a regulatory filing about a legal or capital event. The content matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives.
2019-12-12 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.